✦ LIBER ✦

Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop

✍ Scribed by Raymond T. Chung; Michael Gale Jr; Stephen J. Polyak; Stanley M. Lemon; T. Jake Liang; Jay H. Hoofnagle

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 653 KB
Volume: 47
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.22070

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of interferon alfa 2b

Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C

✍ W. Ray Kim; John J. Poterucha 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 34 KB 👁 2 views

In their paper in the November issue of HEPATOLOGY, Younossi et al. 1 may have overestimated the cost effectiveness of interferon-ribavirin treatment. This mainly stems from their failure to take into account the fact that patients who achieve sustained response are not homogenous with respect to th

Limitation of combination therapy of int

Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C

✍ Yoshiaki Iwasaki; Hiroshi Ikeda; Yasuyuki Araki; Toshiya Osawa; Keiji Kita; Masa 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 2 views

In contrast to the United States, Japanese patients with chronic hepatitis C currently treated with interferon are generally 10 to 15 years older. Older patients, however, tend to experience more frequent adverse events. This study was conducted to clarify the effect of patient age on the efficacy a

Prevalence and impact of occult hepatiti

Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin

✍ Marion Levast; Sylvie Larrat; Marie-Ange Thelu; Sandrine Nicod; Agnès Plages; Al 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

## Abstract The prevalence of occult hepatitis B, defined by absence of HBsAg and HBV DNA, ranges widely in patients with hepatitis C. This may influence the treatment of hepatitis C and the severity of liver disease. Sensitive and specific real‐time PCR techniques are available commercially and ca

Cognitive function does not worsen durin

Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C

✍ Robert J. Fontana; Linas A. Bieliauskas; Karen L. Lindsay; Carla Back-Madruga; E 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 271 KB 👁 1 views

and the HALT-C Trial Group Treatment of chronic hepatitis C with pegylated interferon (peginterferon) and ribavirin can cause or exacerbate depression but its effects on cognitive function are largely unknown. The aim of this study was to determine whether treatment with peginterferon and ribavirin

Peripheral insulin resistance during tre

Peripheral insulin resistance during treatment of chronic hepatitis C with peguilated interferon plus ribavirin

✍ Vivianne Mello; Thomaz Cruz; Geila Nuñez; Maria Tereza Simões; Fabrizio Ney-Oliv 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB

Patients with hepatitis C virus (HCV) infection present higher risk of developing type-2 diabetes mellitus (DM). However, the mechanism of this association and the role of antiviral treatment are still unclear. The objective of this study was to investigate the relationship between the use of peguil

Randomized controlled trial of pegylated

Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6

✍ Khoa D. Lam; Huy N. Trinh; Son T. Do; Thuan T. Nguyen; Ruel T. Garcia; Tuan Nguy 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB 👁 2 views

Hepatitis C virus (HCV) genotype is an important criteria in determining duration of therapy and predictor of sustained virologic response (SVR) to pegylated interferon (PEG IFN) and ribavirin (RBV) therapy. Optimal duration of therapy for patients with HCV genotype 6 is not known. We conducted a mu